

## Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Johanna C. Bendell<sup>1</sup> · Lee S. Rosen<sup>2</sup> · Robert J. Mayer<sup>3</sup> · Jonathan W. Goldman<sup>2</sup> · Jeffrey R. Infante<sup>1</sup> · Fabio Benedetti<sup>4</sup> · Donghu Lin<sup>5</sup> · Hirokazu Mizuguchi<sup>4</sup> · Christopher Zergebel<sup>4</sup> · Manish R. Patel<sup>6</sup>

Published online: 20 November 2015  
© Springer-Verlag Berlin Heidelberg 2015

**Erratum to: Cancer Chemother Pharmacol (2015)  
76:925–932  
DOI 10.1007/s00280-015-2850-4**

Hirokazu Mizuguchi, Fabio Benedetti, and Christopher Zergebel  
Taiho Oncology Inc., 202 Carnegie Center, Suite 100,  
Princeton, NJ 08540, USA

The original version of this article unfortunately contained a mistake. The affiliations of Lee S. Rosen, Jonathan W. Goldman, Hirokazu Mizuguchi, Fabio Benedetti, and Christopher Zergebel are incorrect. The correct affiliations should be:

Lee S. Rosen and Jonathan W. Goldman  
University of California, 2020 Santa Monica Blvd., Suite 600, Santa Monica, CA 90404, USA

---

The online version of the original article can be found under doi:[10.1007/s00280-015-2850-4](https://doi.org/10.1007/s00280-015-2850-4).

---

✉ Johanna C. Bendell  
jbendell@tnonc.com

- <sup>1</sup> Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 200, Nashville, TN 37203, USA
- <sup>2</sup> University of California, 2020 Santa Monica Blvd., Suite 600, Santa Monica, CA 90404, USA
- <sup>3</sup> Dana-Farber Cancer Institute, 450 Brookline Ave., Dana 1602, Boston, MA 02215, USA
- <sup>4</sup> Taiho Oncology Inc., 202 Carnegie Center, Suite 100, Princeton, NJ 08540, USA
- <sup>5</sup> Taiho Pharmaceutical of Beijing Co., Ltd., 9F-9A3, Hanwei Plaza, 7th, Guanghua Rd., Chaoyang Dist., Beijing City 100004, China
- <sup>6</sup> Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL 34232, USA